Tuftsin and tuftsin analogs: Biology, synthesis and design theory

Current Medicinal Chemistry

Volumn 3, Issue 3, 1996, Pages 153-166

  Nishioka, Kenji ^a   McMurray, John ^a   Al Obeidi, Fahad ^b   Pettitt, B Montgomery ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Selectide Corporation   (United States)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUFTSIN; TUFTSIN DERIVATIVE;

COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; IMMUNOMODULATION; MUTANT; NONHUMAN; PHAGOCYTOSIS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0029986202     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Nishioka, K.; Amoscato, A. A.; Badcock, G. F.; Banks, R. A.; Phillips, J. H.: Tuftsin: An immunomodulating peptide hormone and its clinical potential as a natural biological response modifier. Cancer Invest. 1984, 2, 39-49.
2. Nishioka, K.: Tuftsin: A naturally occurring immunomodulating anti tumor tetra peptide. In Sunkara PS (ed), Novel Approaches to Cancer Chemotherapy, Academic Press, N.Y. 1984, pp 251-268.
3. Fridkin, M.; Najjar V.A.: Tuftsin: Its chemistry, biology, and clinical potential. Crit. Rev. Biochem. Mol. Biol. 1989, 24, 1-40, and references cited therein.
4. Najjar, V.A.; Nishioka, K.: "Tuftsin": A physiological phagocytosis stimulating peptide. Nature (London), 1970, 288, 672-673.
5. Nishioka, K.; Satoh, P.S.; Constantopoulos, A.; Najjar, V.A.: The chemical synthesis of the phagocytosis-stimulating tetra peptide tuftsin (Thr-Lys-Pro-Arg) and its biological properties. Biochem. Biophys. J. Acta 1973a, 310, 230-237.
6. Nishioka, K.; Amoscato, A.A.; Badcock, G.F.: Tuftsin: A hormone-like tetra peptide with anti microbial and anti tumor activities. Life Sci. 1981, 28, 1081-1090.
7. Edelman, G. M.; Cunningham, B. A.; Gall, W. E.; Gottlieb, P. D.; Rutishauser. U.;Waxdal, M. J.: The covalent structure of an entire Gimmunoglobulin molecule. Porc. Natl. Acad Sci. 1969, 63, 78-85.
8. Constantopoulos, A.; Najjar, V. A.: Tuftsin, a natural and general phagocytosis stimulating peptide affecting macrophages and polymorphonuclear granulocytes. Cytobios. 1972, 6, 97-100.
9. Bar-Shavit, Z.; Bursuker, I.; Goldman, R.: Functional tuftsin binding sites on macrophage-like tumor line P388D1 and on bone marrow cells differentiated in vitro into mononuclear phagocytes. Mol. Cell Biochem. 1980, 30, 151-155.
10. Amoscato, A. A.; Babcock, G. F.; Nishioka, K.: Analysis of contaminants in commercial preparations of the tetra peptide tuftsin by high-performance liquid chromatography. J. Chromatogr. 1981, 205, 184-197.
11. Najjar, V. A.: Molecular basis of familial and acquired phagocytosis deficiency involving the tetra peptide, Thr-Lys-Pro-Arg, tuftsin. Expl. Cell Biol. 1978, 46, 114-126.
12. Najjar, V. A.; Chauthuri, M. K.; Konopinska, D.; Beck, B.D.; Layne, P. P.; Linehan, L.: Tuftsin (Thr-Lys-Pro-Arg), a physiological activator of phagocytic cells: A possible role in cancer suppression and therapy. In Hersh E.M., Chirigos A, Mastrangelo M. (eds), Augmenting Agents of Cancer Therapy, Raven Press, NY, 1980, pp 459-478.
13. Konopinska, D.; Najjar, V. A.; Callery, M.: Solid-phase synthesis of L-threonyl-L-glutamyl-L-prolyl-L-arginine as the mutant analog of tuftsin. Arch, Immuno. Ther. Exp. 1981, 29, 851-856.
14. Spirer, Z.; Zakuth, V.; Bogair, N.; Fridkin, M.: Radioimmunoassay of the phagocytosis stimulating peptide tuftsin in normal and splenectomized subjects. Eur. J. Immunol. 1977, 7, 69-74.
15. Chu, D. Z. J.; Nishioka, K.; El-Hagin, T.; Hopfer, R.L.; Romsdahl, M. M.: Effects of tuftsin on post-splenectomy sepsis. Surgery 1985, 97, 701-706.
16. Spirer, Z.; Weisman, Y.; Zakuth, V.; Fridkin, M.; Bogair, N.: Decreased serum tuftsin concentrations in sickle cell disease. Arch. Dis. Childhood 1980, 55, 566-567.
17. Constantopoulos, A.; Likhite, V.; Crosby, W. H.; Najjar, V. A.: Phagocytic activity of the leukemic cell and its response to the phagocytosis-stimulating tetra peptide, tuftsin. Cancer Res. 1973, 33, 1230-1234.
18. Fridkin, M.; Stabinsky, Y.; Zakuth, V.; Spirer, Z.: Tuftsin and some analogs: Synthesis and interaction with human polymorphonuclear leukocytes. Biochem. Biophys. Acta 1977, 196, 203-211.
19. Spirer, Z.; Zakuth, V.; Golander, A.; Bogair, N.; Fridkin, M.: The effect of tuftsin on the nitrous blue tetrazolium reduction of normal human polymorphonuclear leukocytes. J. Clin. Invest. 1975, 55, 198-200.
20. Tritsche, G. L.; Niswander, P. U.: Positive correlation between super oxide release and intracellular adenosine deaminase activity during macrophage membrane perturbation regardless of nature of magnitude of stimulus. Mol Cell Biochem 1982, 49, 49-51.
21. Hatung, H. P.; Toyka, V.: Tuftsin stimulates the release of oxygen radicals and thromboxane from macrophages. Immunol. Lett. 1983, 6, 1-6.
22. Martinez, J.; Winternitz, R.; Vindel, J.: Nouvelles syntheses et proprieties de la tuftsine. Eur. J. Med. Chem.-Chim. Ther. 1977, 12, 511-516.
23. Baker, C. C.; Chaudry, I. H.; Gaines, H. O.; Baue, A. E.: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983, 94, 331-335.
24. Nishioka, K.; Hopfer, R. L.; El-Hagin, T.; Lopez-Berestein, G.: Prophylaxis of Candida albicans infection with tuftsin. J. Antimicrobial. Chemother. 1986, 17, 361-363.
25. Kain, Z.; .Alkan, M.; Chaimovitz, C.; Segal, S.; Fridkin, M.; Levy, R.: Human peritoneal macrophage activity is increased by tuftsin. Immunol. Lett. 1989, 21, 257-261.
26. Levy, R.; Kain, Z.; Chaimovitz, C.; Fridkin, M.; Segal, S.; Alkan, M.: Potential use of tuftsin in treatment of candida peritonitis in a murine model. J Biol. Regul. Homeostatic Agents 1989, 3, 71-78.
27. Wleklik, M. S.; Panasiak, W.; Lucsak, M.; Konopinska, D.: Tuftsin, a natural peptide with anti viral activity - Structural basis of its action. Acta Virol. 1988, 32,79-82.
28. Nishioka, K.: In vitro induction of human granulocyte cytotoxcicity by tuftsin. Jpn J. Cancer (Gann) 1979b, 70, 845-846.
29. Nishioka, K.: Anti-tumor effect of the physiological tetra peptide, tuftsin. Br. J. Cancer 1979a, 34, 342-345.
30. Noyes, R. D.; Babcock, G. F.; Nishioka, K.: Anti tumor activity of tuftsin on murine melanoma in viro. Cancer Treat. Rep. 1981, 65, 673-675.
31. Babcock, G. F.; Noyes, R. D.; Nishioka, K.: The effect of tuftsin an immunopotentiating peptide, on Cloudman S-91 melanoma in vivo. Pigment Cell 1981, 1981, 623-628.
32. Sunkara, P. S.; Prakash, E.; Nishioka, K.:Potentiation of anti tumor activity of α-difluormethylornithine by tuftsin. Ann. NY Acad. Sci. 1983, 419, 268-272.
33. Babcock, G.F.; Phillips, J. H.; Nishioka, K.: The immunotherapeutic effect of the peptideon the B cell lymphoma, CH1. In Vitetta E., Fox C.F. (eds), B and T. Cell Tumors: Biological and Clinical Aspects. Academic Press , NY, 1982, 481-485.
34. Banks, R. A.; Nishioka, K.; Kazazi, F.; Babcock, G. F.: Effect of tuftsin on in vivo devel-opment of 3-methylcholanthrene-induced primary fibrosarcoma and Lewis lung carcinoma in mice. J. Natl Cancer Inst. 1985, 74, 1079-1083.
35. Chu, D. Z. J.; Nishioka, K.: Tuftsin increases survival in murine peritoneal carcinomatosis. J. Biol. Response Mod. 1990, 9, 264-267.
36. Catane, R.; Schlanger, S.; Weiss, L.; Penchas, S.; Fuks, Z.; Treves, A. J.; Gottlieb, P.; Fredkin, M.: Toxicology and anti tumor activity of tuftsin. Ann. NY Acad. Sci. 1983, 419, 251-260.
37. Catane, R.; Sulkes, A.; Uziely, B.; Gez, E.; Isacson, R.; Treves, A. J.; Fridkin. M.: Initial clinical studies with tuftsin. Immunotherapy 1986, 2, 81-85.
38. Knyszynski, A.; Gottlieb, P.; Fridkin, M.: Inhibition by tuftsin of Rauscher virus leukemia development in mice. J. Natl. Cancer Inst. 1983, 71, 87-90.
39. Konopinska, D.; Luczak, M.; Wleklik, M.; Gumulka, S.; Dazanowska, B.: Elongated tuftsin analogues - Synthesis and biological investigation. Ann. NY Acad. Sci. 1983, 419, 35-43.
40. Wleklik, M. S.; Ley, S. B.; Lucszk, M.; Najjar, V. A.: Suppression of Friend virus-induced leukemia in mice by tuftsin. J. Gen. Virol. 1986, 67, 2001-2004.
41. Florentin, I., Bruley-Rossett, M.; Kiger, N.; Imbach. J. L.; Winternitz, F.; Mathe. G.; In vivo immunostimulation by tuftsin. Cancer Immunol. Immunother. 1978, 5, 211-216.
42. Fox, A. D.; Chaudry, I. H.; Kupper, T. S.; Green, D. R.; Clemens, M. G.: Baue. A. E.: Restoration of the depressed immune response after burn injury by administration of ATP-MgCl2 or tuftsin. Surgical Forum. 1982, 33, 69-70.
43. Val'dman, A. V.; Ratnikov, V. I.; Makarova, N. V.; Kozlovskaya, M. M.: Toxicology and anti tumor activity of tuftsin. Bull. Exp. Biol. Med. 1983, 95, 604-606.
44. Ohkawa, M.; Chaudry, I. H.; Clemens, M. G.; Hull, M.; Baue, A. E.: Effect of immuno-potentiators on Kupffer cell function and DNA synthesis after ischemia and partial hepatectomy. Surgical Forum 1983, 34, 105-107.
45. Gardner, I. D.: The effect of aging on susceptibility to infection. Rev. Infect. Dis. 1980, 2, 801-810.
46. Wesler, M. E.: Age-associated changes in the immune response. J. Am. Geriatr. Soc. 1982, 30, 718-723.
47. Makinodan, T.: Kay, M. M. B.: Age influence on the immune system. Adv. Immunol. 1980, 29, 287-330.
48. Bruley-Rosset, M.; Hercend, T.; Martinez, J.; Rappaport, H.; Mathe, G.: Prevention of spontaneous tumors of aged mice by immunopharmacologic manipulation: Study of immune anti tumor mechanisms. J. Nat. Cancer Inst. 1981, 66, 1113-1119.
49. Nishioka, K.: Migration enhancement by tuftsin of human mononuclear cells and its effects on the migration inhibition factor test with tumor antigens. Jpn. J. Cancer (Gann) 1978, 69, 569-572.
50. Horsmanheimo, A.; Horsmanheimo, M.; Fudenberg, H. H.: Effect of tuftsin on migration of polymorphonuclear and mononuclear human leukocytes migration agarose test Clin. Immunol. Immunopathol. 1978, 11, 251-255.
51. Giroud, J. P.; Roch-Arveiller. M.; Muntaner, O.; Bradshaw, D.: Action comparee du llev-amisole, du muramyldipeptide et de la tuftsine sur le chimiotactisme des polynucleaires de rat. Nour. Rev. Fr Hemotol. 1980, 22, 69-76.
52. Kavai, M.: Lukacs, K.; Szegedi, G.; Szekerke, M.; Erchegy, J.: Chemotactic and stimulating effect of tuftsin and its analogues on human monocytes. Immuno. Lett. 1981, 2, 219-224.
53. Lukacs, K.; Berenyi, E.; Kavai, M.; Szegedi, G.; Szekerke, M.: Potentiation of the defectivemonocyte chemotaxis in Hodgkin's disease by in vitro tuftsin treatment. Cancer Immunol. Immunother. 1983, 15, 162-163.
54. Lukacs, K.; Szabo, G.; Sonkoly, I.; Vegh, E.; Gacs, J.; Szekerke. M.; Szegedi, G.: Stimulating effect of tuftsin and its analogues on the defective monocyte chemotaxis in systemic lupus erythematosus. Immunopharmacol. 1984, 7, 171-178.
55. Nishioka, K.; Wagle, J. R.: Minter, A. M.; Rodriquez, T., Jr.; Dessens, S. E.: Tuftsin-enhanced thymidine incorporation by murine splenic monocytes. Int. J. Immunopharmacol. 1990, 12, 905908.
56. Bump, N. J.; Najjar, X . A.: Tuftsin stimulates growth of HL60 cells. Febs Lett. 1988, 226, 303-306.
57. Babcock, G. F.; Amoscato, A. A.; Nishioka, K.: Effect of tuftsin on migration, chemotaxis and differentiation of macrophages and granulocytes. Ann. NK Acad. Sci. 1983, 419, 64-74.
58. Tzehoval, E.; Segal, S.; Stabinsky. Y.; Fridkin, M.; Spirer, Z.; Feldman, M.: Tuftsin (an Ig.-associated tetra peptide) triggers the immunogenic function of macrophages: Implications for activation of programmed cells. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 3400-4304.
59. Val'dman, A. V.; Ratnikov, V. I.; Makarova, N. V.; Kozlovskaya, M. M.: Comparison of the effects of tuftsin and some of its analogs on immunogenesis. Bull. Exp. Biol. Med. 1982, 94, 1684-1686.
60. Dagan, S.; Tzehoval, E.; Fridkin, M.; Feldman, M.: Tuftsin and tuftsin conjugates potentate immunogenic processes: Effects and possible mechanisms. J. Biol. Response Mod. 1987, 6, 625-636.
61. Kornberg, A.; Catane, R.; Peller, S.; Kaufman, S.; Fridkin, M.: Tuftsin induces tissue factor-like activity in human mononuclear cells and in monocytic cell lines. Blood 1990, 76, 814-819.
62. Stabinsky, Y.; Gottlieb, P.; Zakuth, V.; Spirer, Z.; Fridkin, M.: Specific binding sites for the phagocytosis stimulating peptide tuftsin on human polymorphonuclear leukocytes and monocytes. Biochem. Biophys. Res. Commun. 1978, 83, 599-6O6.
63. Phillips, J. H.; Babcock, G. F.; Nishioka, K.: Tuftsin: A naturally occurring immuno-potentiating factor I. In vitro enhancement of murine natural cell-mediated cytotoxicity. J. Immunol. 1981, 126, 915-921.
64. Phillips, J. H.; Nishioka, K.; Babcock, G. F.: Tuftsin-induced enhancement of humanand murine natural cell-mediated cytotoxicity. Ann. NY Acad. Sci. 1983, 419, 192-204.
65. Bar-Shavit, Z.; Stabinsky, Y.; Frikdin, M.; Goldman, R.: Tuftsin-macrophage interaction: Specific binding and augmentation of phagocytosis. J. Cell Physiol. 1979, 100, 55-62.
66. Bump, N. J.; Lee, J.; Wleklik, M.; Reichler, J.; Najjar, V. A.: Isolation and subunit composition of tuftsin receptor. Proc. Natl. Acad. Sci. USA 1986, 83, 7187-7191.
67. Bump, N. J.; Najjar, V. A.; Reichler, J.: The characteristics of purified HL60 tuftsin receptors. Mol. Cell Biochem. 1990, 92, 77-84.
68. Stabinsky, Y.; Gottlieb, P.; Fridkin, M.: "The phagocytosis stimulating peptide tuftsin: further look into structure function relationships," Mol. Cell. Biochem. 1980, 30, 165-170.
69. Amoscato, A. A.; Davies, P. J. A.; Babcock, G. F.; Nishioka, K.: Receptor-mediated internalization of tuftsin by human polymorphonuclear leukocytes. J. Reticuloendothel. Sol. 1983, 34, 53-67.
70. Amoscato, A. A.; Davies, P. J. A.; Babcock, G. F.; Nishioka, K.: Receptor-mediated internalization of tuftsin. Ann. NY Acad. Sci. 1983a, 419, 114-134.
71. Wagle, J. R.; Ansevin. A. T.; Dessens; S. B.; Nishioka, K.: Specific translocation of tuftsin (Thr-Lys-Pro-Arg), a natural immunomodulating peptide, into the nuclei of human monocytes. Biochem. Biophys. Res. Commum. 1989, 159, 1147-1153.
72. Florentin, I.; Martinez, J.; Maral. J.; Pelletier, M.; Chung, V.; Roch-Arveiller, M.; Bruley-Rosset, M.; Giroud, J. P.; Winternitz, F.; Mathe, G.: Immunopharmacological properties of tuftsin and of some analogues. Ann. NY Acad. Sci. 1983, 419, 177-191.
73. Wleklik, M. S.; Luczak, M.; Najjar, V. A.: Tuftsin induced tumor necrosis activity. Mol. Cell Biochem. 1987, 75, 169-174.
74. Spirer, Z.; Zakuth, V.; Tzehoval, E.; Dagan, S.; Fridkin, M.; Golander, A.; Melamed. I.: Tuftsin stimulates IL-1 production by human mononuclear cells, human spleen cells and mouse spleen cells in vitro. J. Clin. Lab. Immunol. 1989, 28, 27-31.
75. Mathe, G.; Bruley-Rosset, M.; Rappaport, E.: Conference on Antineoplastic. Immuno-genic and Other Effects of the Tetra peptide Tuftsin: Spontaneous development of tumors on C57b1/6 mice associated with aging. Pharmacoprevention by tuftsin. A Natural Macrophage Activator 1983, 24.
76. Maritus, R.; Spirer, Z; Michaeli, D.; Soferman, G.; Blum, I.: First case of AIDS in a homosexual in Israel. Results of different therapeutic regimens, Isr. J. Med. Sci. 1984, 20, 249-251.
77. Corazza, G. R.; Zoli, G.; Ginaldi, L.; Cancellieri, C.; Profeta, V.; Gasbarrini, G.: Quaglino, D.: Tuftsin deficiency in AIDS. Lancet 1991, 337, 12-13.
78. Nishioka, K.; Constantopoulos, A.; Satoh, P. S. and Najjar, V. A.; "The characteristics, isolation and synthesis of phagocytosis-stimulating peptide tuftsin," Biochem. Biophys. Res. Commun. 1972, 47, 172.
79. Fridkin, M. and Gottlieb, P., "Tuftsin, Thr-Lys-Pro-Arg anatomy of an immunologically active peptide, Mol. Cell Biochem. 1981, 41, 73-97.
80. Siemion, I. Z. and Konopinska, D. "Tuftsin analogs and their biological activity," Mol. Cell Biochem. 1981, 41, 99-112.
81. Gottlieb, P.; Stabinsky, Y.; Zakuth, V.; Spirer, Z., and Fridkin, M., "Synthetic pathwaysto tuftsin and radio immunoassay, Ann. N. Y. Acad. Sci., 1983, 419, 12.
82. Chipens, G. I.; Veremennikova, N. I.; Nikiforovich, G. V.; and Atare, Z. A., "Elongated and cyclic analogues of tuftsin and rigin," in Peptides, Brunfeldt, K. Ed., Scriptor, Copenhagen, 1981, p. 445-450.
83. Filira, F.; Biondi, L.; Cavaggion, F.; Scolaro, B. and Rocchi, R., "Synthesis of Oglycosylated tuftsins by utilizing threonine derivatives containing an unprotected mono-saccharide moiety." Int. J. Peptide Protein Res. 1990, 36, 86-96.
84. 2 modification," J. Med. Chem. 1991, 34, 3372-3379.
85. Mezo, G.; Szekerke, M.; Sarmay, G.; and Gergely, J.: "Synthesis and functional studies of tuftsin analogues containing isopeptide bond," Peptides 1990, 11, 405-415.
86. 3-tuftsin analogue and its α-or ,β-O-D-glucosylated derivatives," Int. J. Peptide Protein Res. 1993, 41, 43-51.
87. Kraus-Berthier, L.; Remond, G.; Visali, M.; Heno, D.; Portevin, B.; Vincent, M.: "In vivo immunopharmacological properties of tuftsin and four analogs," Immunopharmacology 1993, 25, 261-267.
88. Kraus-Berthier, L.; Ferry, G.; Combe-Perez, V.; ViSalli, M.; Remond, G.; Vincent M.; Boutin, J. A.: "Approaches to some Biochemical Mechanisms of Action of Tuftsin and Analogues," Biochemical Pharmacology 1991, 41, 1411-1416.
89. Vincent, M.; Remond, G.; Cudennec, C.A.: "New Peptide Tuftsin Analogues - useful as Immunostimulants," 1986, E.P. 190058.
90. Vincent, M.; Remond, G.; Cudennec, C.A.: "New tripeptides tuftsin analogues containing polycyclic amino acid group useful as Immunostimulant." 1988, E. P. 296059.
91. Paulesi, L.; Di-Stefano, A.; Luzzi, E.; Bocci, V.; Silvestri, S.; Nencioni, L.: "Effect of tuftsin and its retro-inverso analogue on the release of interferon (IFN-gamma) and tumor necrosis factor (TNF-alpha) by human leukocytes Immunol. Lett. 1992, 34, 7-11.
92. Rocchi, R.; Biondi, L; Filira, F.; Gobbo, M.; Dagan, S.; Fridkin, M.: "Synthesis of modified tuftsins containing monosaccharides or monosaccharide units," J. Pept. Prot.Res. 1987a, 29, 250-261.
93. Rocchi, R.; Bionci, L.; Cavaggion, F.; Filira, F.; Gobbo, M.; Dagan, S.; Fridkin. M.:"Synthesis and biological activity of tuftsin and rigin derivatives containing mono-saccharides or monosaccharide derivatives," Int. J. Pept. Prot. Res. 1987b, 29, 262-275.
94. Biondi, L.; Filira, F.; Gobbo, M.; Scolaro, B.; Rocchi, R.: "Synthesis of glycosylated tuftsins and tuftsin-containing IgG fragment undecapeptide," Int. J. Pept Prot. Res.1991, 37, 112-121.
95. Rocchi, R.; Biondi, L.; Filira. F.; Tzehoval, E.; Dagan, S.; Fridkin, M.: "Glyco-tuftsin derivatives modulated interleukin-1 and tumor necrosis factor production," Int. J. Peptide Protein Res., 1991, 37, 161-166.
96. Hruby, V. J.; Al-Obeidi, F. A.; Kazmierski, W. M.: Emerging Approaches in the Molecular Design of Receptor Selective Peptide Ligands: Conformational, Topographical and Dynamic considerations. Biochemical J. 268: 249-262, 1990.
97. Sawyer, T. K.: in " Peptide - Based Drug Design: Controlling Transport & Metabolism" Eds. M.D. Taylor and G. L. Amidon, ACS, Washington, 96D.C., 1995, pp. 387-422.
98. Atherton, E. and Sheppard, R. C.: Solid phase Peptide Synthesis: .4 Practical Approach, Oxford University Press, Oxford, England. 1989.
99. Bodanszky, M. and Bodanszky, A.: The Practice of Peptide Synthesis, Springer-Verlag, New York, NY, 1984.
100. Drylan, A. and Sheppard, R. C.: "The peptide synthesis Part 8. A system for solid-phase synthesis under low pressure continuous flow conditions", J. Chem. Soc. Perkin Trans. 1986, I, 125-137.
101. Fujjino, M.; Wakimasu, M.; Kitade, C.: Chem. Pharm. Bull. (Tokyo), 1981, 29, 2825-2831.
102. Florentin, I.; Chung, V.; Martinez, J.; Maral, J.; LeGarrec, Y.; Mathe, G.: in vivo immunopharmacological properties of tuftsin (Thr-Lys-Pro-Arg) and some analogues. Methods Find. Exp. Clin. Pharmacol. 1986, 8. 73-80.
103. King, D. S.: Fields, C. G.; Fields, G. B.: Int. J. Peptide Protein Res. 1990, 36, 255-266.
104. Andrews, D. M. and Seale, P. W.: "The solid-phase synthesis of O-mannosylated peptides: A comparison of two strategies," in Peptides 1992a, p. 355-356; C. H. Schneider and A.C.H.N. Eberle, editors (Escom Science Publishers B. V.), 1993.
105. Horprich, P. D., Jr.; Bertozzi, C. R.; Bednarski, M. D.: "Solid phase synthesis of carbon-linked glycopeptides," in Peptides, 1992b. p. 367-368, C. H. Schneider, and A.C.H.N. Eberle, editors (Escom Science Publishers B. V.), 1993.
106. Bodanszky, M.: "Active esters in peptide synthesis," in The Peptides: .Analysis. Synthesis,Biology, E. Gross and J. Meienhofer, editors, Vol. I, p. 106-187, Academic Press. Inc., New York, NY, 1979.
107. O'Conner, S. D.; Smith, P. E.; Al-Obeidi, F.; Pettitt, B. M.: "Quenched molecular dynamics simulations of tuftsin and proposed cyclic analogues," J. Med. Chem. 1992, 35, 2870-2881,
108. Nishioka, K.; Obeyesekere, N.U.; MeMurray, J.S., "Enhanced Phagocytosis Activity of Cyclic Analogs of Tuftsin" Biochemical Pharmacology 1995, 49, 735-738.
109. Valdeavella, C.V. Blatt, H.; Pettitt, B.M., "Simulations of Conformation of Tuftsin and Cyclic Tuftsin Analogs", Int. J. Pep. Prof. Res. 1995, 46, 372-380.
110. D'Ursi, A.; Pegna, M.; Amodeo, P.; Molinari, H.; Verdini, A.; Zetta, A.; Tumussi, P.A., "Solution Conformation of Tuftsin", Biochemistry 1995, 31, 9581-9586.